AXSM: Axsome Therapeutics, Inc. Stock

by  •  • Comments Off on AXSM: Axsome Therapeutics, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 4,718.78
Enterprise Value ($M) 4,571.44
Book Value ($M) 92.90
Book Value / Share 1.92
Price / Book 50.80
NCAV ($M) 10.55
NCAV / Share 0.22
Price / NCAV 447.15

Profitability (mra)
Return on Invested Capital (ROIC) -1.10
Return on Assets (ROA) -0.52
Return on Equity (ROE) -1.15

Liquidity (mrq)
Quick Ratio 2.37
Current Ratio 2.44

Balance Sheet (mrq) ($M)
Current Assets 479.11
Assets 561.46
Liabilities 468.56
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-14 13G/A Fairmount Funds Management LLC 4.90 0.64
02-14 13G/A Rtw Investments, Lp 9.50 50.63
02-13 13G/A Vanguard Group Inc 7.81 8.17
01-26 13G/A BlackRock, Inc. 6.80 29.44

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT
2024-08-05 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO S
2024-05-06 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO
2024-02-23 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-11-15 127,555 644,441 19.79
2024-11-14 140,996 562,287 25.08
2024-11-13 259,790 1,124,553 23.10
2024-11-12 305,092 1,498,597 20.36
2024-11-11 106,272 594,112 17.89

(click for more detail)

Similar Companies
AVBP – ArriVent BioPharma, Inc. AVDL – Avadel Pharmaceuticals plc
AVTE – Aerovate Therapeutics, Inc. BCAB – BioAtla, Inc.
BHST – BioHarvest Sciences Inc.


Financial data and stock pages provided by
Fintel.io

Finpedia: Axsome Therapeutics